Conference item : Abstract
The JAK1-selective inhibitor filgotinib reverses the disease-associated transcriptional profile found in the blood of patients with active rheumatoid arthritis
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 16.6KB, Terms of use)
-
- Publisher copy:
- 10.1002/art.40700
Authors
- Publisher:
- Wiley
- Host title:
- Arthritis and Rheumatology
- Journal:
- Arthritis and Rheumatology More from this journal
- Volume:
- 70
- Issue:
- S9
- Pages:
- Abstract: 2517
- Publication date:
- 2018-10-15
- Acceptance date:
- 2018-08-14
- Event location:
- Chicago, Illinois
- DOI:
- EISSN:
-
2326-5205
- ISSN:
-
2326-5191
- Keywords:
- Subtype:
-
Abstract
- Pubs id:
-
pubs:922559
- UUID:
-
uuid:c8523e5b-9903-4b71-9b4a-2cf5589708e1
- Local pid:
-
pubs:922559
- Source identifiers:
-
922559
- Deposit date:
-
2018-10-01
- ARK identifier:
Terms of use
- Copyright holder:
- American College of Rheumatology
- Copyright date:
- 2018
- Notes:
- © 2018, American College of Rheumatology. This conference item was presented at the American College of Rheumatology Annual Meeting 2018. This is the accepted manuscript version of the abstract. The final version is available online from Wiley at: https://doi.org/10.1002/art.40700
If you are the owner of this record, you can report an update to it here: Report update to this record